Once-weekly Isoniazid and Rifapentine for 12 Weeks for the Treatment of Latent Tuberculosis Infection: Clinical Utility and Cost-Effectiveness


( Last Updated : August 14, 2020)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1129-000

Details


Question


  1.  What is the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?

  2.  What is the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?

     




Key Message

Two systematic reviews with meta-analyses, one systematic review with a network meta-analysis, five randomized controlled trials and ten non-randomized studies were identified regarding the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection. Additionally, two economic evaluations were identified regarding the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection.